|本期目录/Table of Contents|





Pathophysiology and therapeutics in cardiovascular disease of patients with metabolic syndrome: research progress
江振华王亚斌曹 丰
(第四军医大学西京医院心内科,陕西 西安 710032)
JIANG Zhen-hua WANG Ya-bin CAO Feng
(Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)
metabolic syndrome cardiovascular disease pathophysiological process combined treatment
Metabolic syndrome (MetS) is the pathological state of abnormal accumulation of various metabolites that always manifest a series of syndromes characterized by cardiovascular risk factors including central obesity, hyperglycemia, dyslipidemia and hypertension, which are highly correlated with the growing morbidity and mortality rates for cardiovascular diseases (CVD). The correlation between these metabolic disorders and the development of CVD is identified to be complex and multifactorial in which insulin resistance (IR), oxidative stress, low-grade inflammation and vascular maladaptation are considered to be the leading causes. Hence, multifaceted comprehensive treatment scheme should be used to treat patients with MetS. Lifestyle changes such as weight control, healthy heart diet and regular exercises have been recommended as the first line measures to reduce the risks of CVD in MetS individuals. Improving insulin resistance and glucose metabolism, controlling blood pressure and adjusting dyslipidemia can also reverse or slow down the process of CVD in MetS. This review aims to elaborate the complex relationship between MetS and CVD, to discuss the optimal treatment regimens to prevent and treat cardiovascular complications in MetS patients and to introduce the updated results from newly released clinical trials.


[1]Ogden CL,Carroll MD,Kit BK,et al.Prevalence of obesity and trends in body mass index among US children and adolescents,1999-2010[J].JAMA,2012,307(5):483-490.
[2]Guize L,Pannier B,Thomas F,et al.Recent advances in metabolic syndrome and cardiovascular disease[J].Arch Cardiovasc Dis,2008,101(9):577-583.
[3]Berwick ZC, Dick GM,Tune JD.Heart of the matter:coronary dysfunction in metabolic syndrome[J].J Mol Cell Cardiol,2012,52(4):848-856.
[4]Gauthier MS,Ruderman NB.Adipose tissue inflammation and insulin resistance:all obese humans are not created equal[J].Biochem J,2010,430(2):e1-e4.
[5]Reddy KJ,Singh M,Bangit JR,et al.The role of insulin resistance in the pathogenesis of atherosclerotic cardiovascular disease:an updated review[J].J Cardiovasc Med (Hagerstown), 2010, 11(9):633-647.
[6]Reaven GM. Insulin resistance: the link between obesity and cardiovascular disease[J].Med Clin North Am,2011,95(5):875-892.
[7]Leroith D.Pathophysiology of the metabolic syndrome:implications for the cardiometabolic risks associated with type 2 diabetes[J].Am J Med Sci,2012,343(1):13-16.
[8]Yamagishi S.Cardiovascular disease in recent onset diabetes mellitus[J].J Cardiol,2011,57(3):257-262.
[9]Lavie CJ,Milani RV,O’keefe JH.Dyslipidemia intervention in metabolic syndrome:emphasis on improving lipids and linical event reduction[J].Am J Med Sci,2011,341(5):388-393.
[10]Raal FJ.Pathogenesis and management of the dyslipidemia of the metabolic syndrome[J].Metab Syndr Relat Disord,2009,7(2):83-88.
[11]Morales-Suarez-Varela MM,Mansego ML,Vicedo-Cabrera AM,et al.Inefficient arterial hypertension control in patients with metabolic syndrome and its link to renin-angiotensin-aldosterone system polymorphisms[J].Hypertens Res,2011,34(6):758-766.
[12]Chaudhary K,Buddineni JP,Nistala R,et al.Resistant hypertension in the high-risk metabolic patient[J].Curr Diab Rep,2011,11(1):41-46.
[13]Suehiro A,Wakabayashi I,Uchida K,et al.Impaired spontaneous thrombolytic activity measured by global thrombosis test in males with metabolic syndrome[J].Thromb Res,2012,129(4):499-501.
[14]Mauras N,Delgiorno C,Kollman C,et al.Obesity without established comorbidities of the metabolic syndrome is associated with a proinflammatory and prothrombotic state, even before the onset of puberty in children[J].J Clin Endocrinol Metab,2010,95(3):1060-1068.[15]Svendsen M,Helgeland M,Tonstad S.The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome[J].J Hum Nutr Diet,2009,22(1):55-63.
[16]Nagayama D,Shirai K.Sibutramine and its adequate usage[J].Nihon Rinsho,2011,69(Suppl 1):678-682.
[17]Woodward M,Patel A,Zoungas S,et al.Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial[J].Diabetes Care,2011,34(12):2491-2495.
[18]Schernthaner G.Diabetes and Cardiovascular Disease:Is intensive glucose control beneficial or deadly? Lessons from ACCORD,ADVANCE,VADT,UKPDS,PROactive,and NICE-SUGAR[J].Wien Med Wochenschr,2010,160(1-2):8-19.
[19]Muhlhauser I.Follow-up of intensive glucose control in type 2 diabetes[J].N Engl J Med,2009,360(4):417;author reply 418.
[20]Erdmann E,Wilcox RG.Weighing up the cardiovascular benefits of thiazolidinedione therapy:the impact of increased risk of heart failure[J].Eur Heart J,2008,29(1):12-20.
[21]Swislocki AL,Siegel D,Jialal I.Pharmacotherapy for the metabolic syndrome[J].Curr Vasc Pharmacol,2012,10(2):187-205.
[22]Nakajima K.Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome[J].Curr Clin Pharmacol,2010,5(2):133-139.
[23]Einhorn PT,Davis BR,Wright JT,et al.ALLHAT:still providing correct answers after 7 years[J].Curr Opin Cardiol,2010,25(4):355-365.
[24]Stafylas PC, Sarafidis PA. Carvedilol in hypertension treatment[J]. Vasc Health Risk Manag, 2008, 4(1):23-30.
[25]Yamada S,Ano N,Toda K,et al.Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro[J].Hypertens Res,2008,31(4):601-606.
[26]Santilli F,Vazzana N,Liani R,et al.Platelet activation in obesity and metabolic syndrome[J].Obes Rev,2012,13(1):27-42.
[27]Vendrell J,El Bekay R,Peral B,et al.Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance[J].Endocrinology,2011,152(11):4072-4079.


通讯作者:曹丰,主任医师,主要从事心肌再生机制及干预在体分子影像研究 Email:fengcao@fmmu.edu.cn
作者简介:江振华,硕士生 Email:jzhfmmu@163.com
更新日期/Last Update: 2014-06-05